ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Remicade (Infliximab) and Biosimilar Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-5O14665
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Remicade Infliximab and Biosimilar Market Research Report 2023
BUY CHAPTERS

Global Remicade (Infliximab) and Biosimilar Market Research Report 2025

Code: QYRE-Auto-5O14665
Report
May 2025
Pages:72
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
J & J
Pfizer Inc
Amgen Inc
Organon

Remicade (Infliximab) and Biosimilar Market Size

The global market for Remicade (Infliximab) and Biosimilar was valued at US$ 2920 million in the year 2024 and is projected to reach a revised size of US$ 4253 million by 2031, growing at a CAGR of 5.6% during the forecast period.

Remicade (Infliximab) and Biosimilar Market

Remicade (Infliximab) and Biosimilar Market

Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn"s disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
North American market for Remicade (Infliximab) and Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Remicade (Infliximab) and Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Remicade (Infliximab) and Biosimilar include J & J, Pfizer, Organon, Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Remicade (Infliximab) and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade (Infliximab) and Biosimilar.
The Remicade (Infliximab) and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Remicade (Infliximab) and Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Remicade (Infliximab) and Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Remicade (Infliximab) and Biosimilar Market Report

Report Metric Details
Report Name Remicade (Infliximab) and Biosimilar Market
Accounted market size in year US$ 2920 million
Forecasted market size in 2031 US$ 4253 million
CAGR 5.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Brand
  • Biosimilar
Segment by Application
  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company J & J, Pfizer, Organon, Amgen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Remicade (Infliximab) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Remicade (Infliximab) and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Remicade (Infliximab) and Biosimilar Market growing?

Ans: The Remicade (Infliximab) and Biosimilar Market witnessing a CAGR of 5.6% during the forecast period 2025-2031.

What is the Remicade (Infliximab) and Biosimilar Market size in 2031?

Ans: The Remicade (Infliximab) and Biosimilar Market size in 2031 will be US$ 4253 million.

Who are the main players in the Remicade (Infliximab) and Biosimilar Market report?

Ans: The main players in the Remicade (Infliximab) and Biosimilar Market are J & J, Pfizer, Organon, Amgen

What are the Application segmentation covered in the Remicade (Infliximab) and Biosimilar Market report?

Ans: The Applications covered in the Remicade (Infliximab) and Biosimilar Market report are Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, Other

What are the Type segmentation covered in the Remicade (Infliximab) and Biosimilar Market report?

Ans: The Types covered in the Remicade (Infliximab) and Biosimilar Market report are Brand, Biosimilar

Recommended Reports

Biosimilar Markets

Rheumatic Disease Therapies

Injectable Therapies

1 Remicade (Infliximab) and Biosimilar Market Overview
1.1 Product Definition
1.2 Remicade (Infliximab) and Biosimilar by Type
1.2.1 Global Remicade (Infliximab) and Biosimilar Market Value Comparison by Type (2024 VS 2031)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Remicade (Infliximab) and Biosimilar by Application
1.3.1 Global Remicade (Infliximab) and Biosimilar Market Value by Application (2024 VS 2031)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Remicade (Infliximab) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Remicade (Infliximab) and Biosimilar Revenue 2020-2031
1.4.2 Global Remicade (Infliximab) and Biosimilar Sales 2020-2031
1.4.3 Global Remicade (Infliximab) and Biosimilar Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Remicade (Infliximab) and Biosimilar Market Competition by Manufacturers
2.1 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Manufacturers (2020-2025)
2.2 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Remicade (Infliximab) and Biosimilar Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Remicade (Infliximab) and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Product Type & Application
2.7 Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Date of Enter into This Industry
2.8 Global Remicade (Infliximab) and Biosimilar Market Competitive Situation and Trends
2.8.1 Global Remicade (Infliximab) and Biosimilar Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Remicade (Infliximab) and Biosimilar Players Market Share by Revenue
2.8.3 Global Remicade (Infliximab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Remicade (Infliximab) and Biosimilar Market Scenario by Region
3.1 Global Remicade (Infliximab) and Biosimilar Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2020-2031
3.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2020-2025
3.2.2 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2026-2031
3.3 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2020-2031
3.3.1 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2020-2025
3.3.2 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2026-2031
3.4 North America Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Remicade (Infliximab) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Remicade (Infliximab) and Biosimilar Sales by Country (2020-2031)
3.4.3 North America Remicade (Infliximab) and Biosimilar Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Remicade (Infliximab) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Remicade (Infliximab) and Biosimilar Sales by Country (2020-2031)
3.5.3 Europe Remicade (Infliximab) and Biosimilar Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Remicade (Infliximab) and Biosimilar Market Facts & Figures by Region
3.6.1 Asia Pacific Remicade (Infliximab) and Biosimilar Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Region (2020-2031)
3.6.3 Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Remicade (Infliximab) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Remicade (Infliximab) and Biosimilar Sales by Country (2020-2031)
3.7.3 Latin America Remicade (Infliximab) and Biosimilar Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Remicade (Infliximab) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Remicade (Infliximab) and Biosimilar Sales by Country (2020-2031)
3.8.3 Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2020-2031)
4.1.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2020-2025)
4.1.2 Global Remicade (Infliximab) and Biosimilar Sales by Type (2026-2031)
4.1.3 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2020-2031)
4.2 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2020-2031)
4.2.1 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2020-2025)
4.2.2 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2026-2031)
4.2.3 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2020-2031)
4.3 Global Remicade (Infliximab) and Biosimilar Price by Type (2020-2031)
5 Segment by Application
5.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2020-2031)
5.1.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2020-2025)
5.1.2 Global Remicade (Infliximab) and Biosimilar Sales by Application (2026-2031)
5.1.3 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2020-2031)
5.2 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2020-2031)
5.2.1 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2020-2025)
5.2.2 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2026-2031)
5.2.3 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2020-2031)
5.3 Global Remicade (Infliximab) and Biosimilar Price by Application (2020-2031)
6 Key Companies Profiled
6.1 J & J
6.1.1 J & J Company Information
6.1.2 J & J Description and Business Overview
6.1.3 J & J Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.1.4 J & J Remicade (Infliximab) and Biosimilar Product Portfolio
6.1.5 J & J Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer Remicade (Infliximab) and Biosimilar Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Organon
6.3.1 Organon Company Information
6.3.2 Organon Description and Business Overview
6.3.3 Organon Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Organon Remicade (Infliximab) and Biosimilar Product Portfolio
6.3.5 Organon Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Company Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Amgen Remicade (Infliximab) and Biosimilar Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Remicade (Infliximab) and Biosimilar Industry Chain Analysis
7.2 Remicade (Infliximab) and Biosimilar Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Remicade (Infliximab) and Biosimilar Production Mode & Process Analysis
7.4 Remicade (Infliximab) and Biosimilar Sales and Marketing
7.4.1 Remicade (Infliximab) and Biosimilar Sales Channels
7.4.2 Remicade (Infliximab) and Biosimilar Distributors
7.5 Remicade (Infliximab) and Biosimilar Customer Analysis
8 Remicade (Infliximab) and Biosimilar Market Dynamics
8.1 Remicade (Infliximab) and Biosimilar Industry Trends
8.2 Remicade (Infliximab) and Biosimilar Market Drivers
8.3 Remicade (Infliximab) and Biosimilar Market Challenges
8.4 Remicade (Infliximab) and Biosimilar Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
J & J
Pfizer Inc
Amgen Inc
Organon
List of Tables
 Table 1. Global Remicade (Infliximab) and Biosimilar Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Remicade (Infliximab) and Biosimilar Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Remicade (Infliximab) and Biosimilar Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Remicade (Infliximab) and Biosimilar Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Remicade (Infliximab) and Biosimilar Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Remicade (Infliximab) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Remicade (Infliximab) and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Product Type & Application
 Table 12. Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Remicade (Infliximab) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Remicade (Infliximab) and Biosimilar as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Remicade (Infliximab) and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Remicade (Infliximab) and Biosimilar Sales by Region (2020-2025) & (K Units)
 Table 18. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Region (2020-2025)
 Table 19. Global Remicade (Infliximab) and Biosimilar Sales by Region (2026-2031) & (K Units)
 Table 20. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Region (2026-2031)
 Table 21. Global Remicade (Infliximab) and Biosimilar Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Region (2020-2025)
 Table 23. Global Remicade (Infliximab) and Biosimilar Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Region (2026-2031)
 Table 25. North America Remicade (Infliximab) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Remicade (Infliximab) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 27. North America Remicade (Infliximab) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 28. North America Remicade (Infliximab) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Remicade (Infliximab) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Remicade (Infliximab) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Remicade (Infliximab) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Remicade (Infliximab) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Remicade (Infliximab) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Remicade (Infliximab) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Remicade (Infliximab) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Remicade (Infliximab) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Remicade (Infliximab) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Remicade (Infliximab) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Remicade (Infliximab) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Remicade (Infliximab) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Remicade (Infliximab) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Remicade (Infliximab) and Biosimilar Sales (K Units) by Type (2020-2025)
 Table 51. Global Remicade (Infliximab) and Biosimilar Sales (K Units) by Type (2026-2031)
 Table 52. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2020-2025)
 Table 53. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2026-2031)
 Table 54. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2020-2025)
 Table 57. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2026-2031)
 Table 58. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Remicade (Infliximab) and Biosimilar Sales (K Units) by Application (2020-2025)
 Table 61. Global Remicade (Infliximab) and Biosimilar Sales (K Units) by Application (2026-2031)
 Table 62. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2020-2025)
 Table 63. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2026-2031)
 Table 64. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2020-2025)
 Table 67. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2026-2031)
 Table 68. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Application (2026-2031)
 Table 70. J & J Company Information
 Table 71. J & J Description and Business Overview
 Table 72. J & J Remicade (Infliximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. J & J Remicade (Infliximab) and Biosimilar Product
 Table 74. J & J Recent Developments/Updates
 Table 75. Pfizer Company Information
 Table 76. Pfizer Description and Business Overview
 Table 77. Pfizer Remicade (Infliximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Pfizer Remicade (Infliximab) and Biosimilar Product
 Table 79. Pfizer Recent Developments/Updates
 Table 80. Organon Company Information
 Table 81. Organon Description and Business Overview
 Table 82. Organon Remicade (Infliximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Organon Remicade (Infliximab) and Biosimilar Product
 Table 84. Organon Recent Developments/Updates
 Table 85. Amgen Company Information
 Table 86. Amgen Description and Business Overview
 Table 87. Amgen Remicade (Infliximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Amgen Remicade (Infliximab) and Biosimilar Product
 Table 89. Amgen Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Remicade (Infliximab) and Biosimilar Distributors List
 Table 93. Remicade (Infliximab) and Biosimilar Customers List
 Table 94. Remicade (Infliximab) and Biosimilar Market Trends
 Table 95. Remicade (Infliximab) and Biosimilar Market Drivers
 Table 96. Remicade (Infliximab) and Biosimilar Market Challenges
 Table 97. Remicade (Infliximab) and Biosimilar Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Remicade (Infliximab) and Biosimilar
 Figure 2. Global Remicade (Infliximab) and Biosimilar Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Remicade (Infliximab) and Biosimilar Market Share by Type: 2024 & 2031
 Figure 4. Brand Product Picture
 Figure 5. Biosimilar Product Picture
 Figure 6. Global Remicade (Infliximab) and Biosimilar Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Remicade (Infliximab) and Biosimilar Market Share by Application: 2024 & 2031
 Figure 8. Ankylosing Spondylitis
 Figure 9. Rheumatoid Arthritis
 Figure 10. Crohn’s Disease
 Figure 11. Other
 Figure 12. Global Remicade (Infliximab) and Biosimilar Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Remicade (Infliximab) and Biosimilar Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Remicade (Infliximab) and Biosimilar Sales (2020-2031) & (K Units)
 Figure 15. Global Remicade (Infliximab) and Biosimilar Average Price (US$/Unit) & (2020-2031)
 Figure 16. Remicade (Infliximab) and Biosimilar Report Years Considered
 Figure 17. Remicade (Infliximab) and Biosimilar Sales Share by Manufacturers in 2024
 Figure 18. Global Remicade (Infliximab) and Biosimilar Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Remicade (Infliximab) and Biosimilar Players: Market Share by Revenue in Remicade (Infliximab) and Biosimilar in 2024
 Figure 20. Remicade (Infliximab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Remicade (Infliximab) and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 23. North America Remicade (Infliximab) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 24. United States Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 27. Europe Remicade (Infliximab) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Remicade (Infliximab) and Biosimilar Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Remicade (Infliximab) and Biosimilar Revenue Market Share by Region (2020-2031)
 Figure 35. China Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. China Taiwan Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Latin America Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 43. Latin America Remicade (Infliximab) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 44. Mexico Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Brazil Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Argentina Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of Remicade (Infliximab) and Biosimilar by Type (2020-2031)
 Figure 53. Global Revenue Market Share of Remicade (Infliximab) and Biosimilar by Type (2020-2031)
 Figure 54. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of Remicade (Infliximab) and Biosimilar by Application (2020-2031)
 Figure 56. Global Revenue Market Share of Remicade (Infliximab) and Biosimilar by Application (2020-2031)
 Figure 57. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Application (2020-2031)
 Figure 58. Remicade (Infliximab) and Biosimilar Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Remicade Infliximab Monoclonal Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Remicade infliximab Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Infliximab Injection Market Research Report 2024
Biosimilar of Remicade Market
Adalimumab Humira and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Humira Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti TNF α Monoclonal Antibody Market Insights Forecast to 2030
Global Adalimumab Infliximab And Etanercept Biosimilars Market Research Report 2024
Global Rituximab Biosimilars Market Research Report 2025
Enbrel Etanercept and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ustekinumab Biosimilars Market Research Report 2024
Global TNF Inhibitors for the Treatment of Rheumatoid Arthritis Market Research Report 2024
Global Tumor Necrosis Factor Alpha Inhibitors Market Research Report 2024
Global Recombinant Human Tumor Necrosis Factor α ReceptorⅡ IgG Fc Fusion Protein for Injection Market Research Report 2024
Global Etanercept Solution for Injection Market Research Report 2024
Oncology Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Psoriasis Biosimilar Market Research Report 2024
Global Ranibizumab Drugs and Biosimilars Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions